DK2970202T3 - Pyridinyl- og fusionerede pyridinyltriazolonderivater - Google Patents
Pyridinyl- og fusionerede pyridinyltriazolonderivater Download PDFInfo
- Publication number
- DK2970202T3 DK2970202T3 DK14719130.8T DK14719130T DK2970202T3 DK 2970202 T3 DK2970202 T3 DK 2970202T3 DK 14719130 T DK14719130 T DK 14719130T DK 2970202 T3 DK2970202 T3 DK 2970202T3
- Authority
- DK
- Denmark
- Prior art keywords
- triazol
- compound
- mmol
- oxy
- isoquinolin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (26)
- 1. Forbindelse med formel 1, 1 en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren, hvor: R1 er udvalgt blandt hydrogen, halogen, -CN, Ci-4alkyl, Ci-4halogenalkyl og -OR14; R2 og R3 hver for sig er udvalgt blandt hydrogen, halogen, -CN, Rs og R7, eller R2 og R3 sammen med carbonatomer, hvortil de er bundet, danner en benzenring eller en pyridinring, hvor benzenringen eventuelt er substitueret med fra en til fire substituenter udvalgt uafhængigt blandt halogen, -CN, R6 og R7, og pyridinringen eventuelt er substitueret med fra en til tre substituenter udvalgt uafhængigt blandt halogen, -CN, R6 og R7; R4 har formlenhvori ^ angiver et tilkoblingspunkt; L er udvalgt blandt -0-, -CH2O- og -N(R4e)-; R4a er udvalgt blandt -CH2R5 og ethenyl, der eventuelt er substitueret med fra en til tre substituenter udvalgt uafhængigt blandt halogen, cyano og R7; og (a) R4c er hydrogen, R4e er udvalgt blandt hydrogen og Ci-4alkyl, når L er -N (R4e) - og R4b og R4d sammen med et nitrogenatom og carbonatomer, hvortil R4b, R4c og R4d er bundet, danner en pyrrolidinring eller en piperidinring, idet hver ring eventuelt er substitueret med fra en til seks substituenter udvalgt uafhængigt blandt halogen, Ci-4alkyl og Ci- 4halogenalkyl; eller (b) R4b er udvalgt blandt hydrogen og Ci-4alkyl, R4d er hydrogen, L er -N (R4e) - og R4c og R4e sammen med carbonatomerne og et nitrogenatom, hvortil R4c, R4d og R4e er bundet, danner en pyrrolidinring eller en piperidinring, idet hver ring eventuelt er substitueret med fra en til seks substituenter udvalgt uafhængigt blandt halogen, Ci-jalkyl og Ci- 4halogenalkyl; eller (c) R4d er hydrogen, R4e er udvalgt blandt hydrogen og Ci-4alkyl, når L er -N(R4e)-, og R4b og R4c sammen med nitrogen- og carbonatomerne, hvortil R4b og R4c er bundet, danner en pyrrolidinring eller en piperidinring, idet hver ring eventuelt er substitueret med fra en til seks substituenter udvalgt uafhængigt blandt halogen, Ci-4alkyl og Ci- 4halogenalkyl ; R5 er udvalgt blandt hydrogen, halogen og Ci-^alkyl; hver R6 er udvalgt uafhængigt blandt -OR8, -N(R8)R9, -NR8C(0)R9, -NHC (0) NR8R9, -NR3C (0) NHR9, -C(0)R8, -C(0)0R8, -C (0) N (R8) R9, - C (0)N (R8) OR9, -C (0)N (R8) S (0) 2R7, -N (R8) S (0) 2R7, -SR8, -S(0)R7, - S(0)2R7 og -S(0) 2N (R8) R9; hver R7 er udvalgt uafhængigt blandt (a) Ci-6alkyl, C2-6alkenyl og C2-6alkynyl, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN og R10; og (b) C3-iocycloalkyl-(CH2)m-, C6-i4aryl-(CH2) m-, C2-6heterocyclyl- (CH2)rr- og Ci-gheteroaryl-(CH2)m-, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN, R10 og Ci-6alkyl, der eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN og R10; hver R8 og R9 er udvalgt uafhængigt blandt (a) hydrogen; (b) Ci-6alkyl, C2-6alkenyl og C2-6alkynyl, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN og R10; og (c) Cs-iocycloalkyl-(CH2)m-, C6-i4aryl-(CH2) m-, C2-6heterocyclyl- (CH2) ir.— og Ci-9heteroaryl-(CH2)m-, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN, R10 og Ci-ealkyl, der eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN og R10; hver R10 er udvalgt uafhængigt blandt -OR11, -N(Rn)R12, N (R11) C (O) R12, -NHC (O) NRnR12, -NRnC (O) NHR12, -C(0)Rn, -C(0)0Rn, -C (O) N (R11) R12, -C (O)N (R11) OR12, -C (O) N (R11) S (O) 2R13, -NR41S (O) 2R13, -SR11, -S(0)R13, -S(0)2R13 og -S (O) 2N (R11) R12; hver R11 og R12 er udvalgt uafhængigt blandt (a) hydrogen; og (b) Ci-6alkyl og C3-iocycloalkyl-(CH2) π—, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN, -OH og -NH2; hver R13 er udvalgt uafhængigt blandt Ci-6alkyl og C3-locycloalkyl-(CH2) m-, der hver eventuelt er substitueret med fra en til fem substituenter udvalgt uafhængigt blandt halogen, oxo, -CN, -OH og -NH2; hver R14 er udvalgt uafhængigt blandt hydrogen, Ci-4alkyl og Ci-4halogenalkyl; og hver m er udvalgt uafhængigt blandt 0, 1, 2, 3 og 4; hvor hver heteroaryl og heterocyclyl af R7, R8 og R9 uafhængigt har en til fire heteroatomer, hvor hvert af heteroatomerne er udvalgt uafhængigt blandt N, O og S.
- 2. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge krav 1, hvor R1 er hydrogen.
- 3. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af ovennævnte krav, hvor R2 og R3 sammen med carbonatomerne, hvortil de er bundet, danner en benzenring eller en pyridinring, hvor benzenringen eventuelt er substitueret med fra en til fire substituenter udvalgt uafhængigt blandt halogen, -CN, R6 og R7, og pyridinringen eventuelt er substitueret med fra en til tre substituenter udvalgt uafhængigt blandt halogen, -CN, R6 og R7.
- 4. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af ovennævnte krav, hvor R4a er usubstitueret ethenyl.
- 5. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af ovennævnte krav, hvor R4c er hydrogen, R4e er udvalgt blandt hydrogen og Ci-4alkyl, når L er -N(R4e)-, og R4b og R4d sammen med nitrogenatomet og carbonatomerne, hvortil R4b, R4c og R4d er bundet, danner en pyrrolidinring eller en piperidinring, hvor hver ring eventuelt er substitueret med fra en til seks substituenter udvalgt uafhængigt blandt halogen, Ci-4alkyl og Ci- 4halogenalkyl.
- 6. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge krav 5, hvor R4b og R4d sammen med nitrogenatomet og carbonatomerne, hvortil R4b, R4c og R4d er bundet, danner en pyrrolidinring, der eventuelt er substitueret med fra en til fire substituenter udvalgt uafhængigt blandt halogen, Ci-4alkyl og Ci-4halogenalkyl.
- 7. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 5-6, hvor ringen dannet af R4b og R4d sammen med nitrogenatomet og carbonatomerne, hvortil R4b, R4c og R4d er bundet, er usubstitueret.
- 8. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af ovennævnte krav, hvor L er -N (R4e) -.
- 9. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-7, hvor L er -0-.
- 10. Forbindelse ifølge krav 1, der er udvalgt blandt følgende forbindelser: (R)-3-(1-((l-methacryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (R) -3-(1-((l-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H- l,2,4-triazol-5(4H)-on; (R,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; N-(1-(3-(5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl)isoquinolin-1-yl)pyrrolidin-3-yl)acrylamid; (S) -3-(1-((l-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-IH- 1,2,4-triazol-5(4H)-on; (S)-3-(1-(((l-acryloylpyrrolidin-2- yl)methyl)amino)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-2-yl)methoxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3-yl) amino)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (R) -3-(1-((l-acryloylpyrrolidin-2-yl)methoxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5 (4H)-on; (S) -3-(1-((l-methacryloylpyrrolidin-3-yl) amino)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3- yl)(methyl)amino)isoquinolin-3-yl)-IH-1,2,4-triazol-5(4H)-on; (S)-3- (1- ( (l-methacryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-IH-1,2,4-triazol-5(4H)-on; (S)-3-(1-(((l-acryloylpyrrolidin-3-yl)oxy)methyl)isoquinolin-3-yl)-1H-1,2,4-triazol-5 (4H)-on; (S,E)-5-(1-((1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-l,2,4-triazol-3-on; (S,E)-3 - (1- ( (1- (but-2-enoyl) pyrrolidin-3-yl) amino)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S) -3-(8-((l-acryloylpyrrolidin-3-yl)oxy)-1,7-naphthyridin-6-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(8-((l-acryloylpyrrolidin-3-yl) amino)-1,7-naphthyridin-6-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3-yl)oxy)-7-fluorisoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; 3-(1-((trans-l-acryloyl-4-methylpyrrolidin-3- yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; 3-(1-(((3R, 4S)-l-acryloyl-4-methylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; 3-(1-(((3 S,4R)-l-acryloyl-4-methylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3-yl)oxy)-8-fluorisoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3-yl) amino)-8-fluorisoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; (S)-3-(1-((l-acryloylpyrrolidin-3-yl)oxy)-7-chlorisoquinolin- 3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)_3_ (i- ( (l-acryloylpyrrolidin-3-yl) amino)-7-fluorisoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; (3) _3_ (]__ ( (l-acryloylpyrrolidin-3-yl) amino) -7-chlorisoquinolin-3-yl)-lH-l,2,4-triazol-5(4H)-on; (S)_3_(i-((l-acryloylpyrrolidin-3-yl)oxy)-8-chlorisoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(i-((l-acryloylpyrrolidin-3-yl)amino)-8-chlorisoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S) -3-(1-((l-acryloylpyrrolidin-3-yl)amino)-8-methoxyisoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(6-((l-acryloylpyrrolidin-3-yl)oxy)-4-methylpyridin-2-yl)-1H-1,2,4-triazol-5(4H)-on; (S)-3-(6-((l-acryloylpyrrolidin-3-yl)oxy)pyridin-2-yl)-1H- 1.2.4- triazol-5(4H)-on; (S)-3-(6-((l-acryloylpyrrolidin-3-yl)oxy)-5-methylpyridin-2-yl)-1H-1,2,4-triazol-5(4H)-on; (S)—5 — (1— ( (1—(2-chloracetyl) pyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-l,2,4-triazol-3-on; (S)-5-(1-((1-(2-chloracetyl)pyrrolidin-3-yl)amino)isoquinolin-3-yl)-2,4-dihydro-3H-l,2,4-triazol-3~on; (S)-5-(1-((1-acryloylpiperidin-3-yl)oxy)isoquinolin-3-yl) -2,4-dihydro-3H-l,2,4-triazol-3-on; (S)-5-(1-((l-acetylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-l,2,4-triazol-3-on; (S)-5- (1-( (l-propionylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)- 2.4- dihydro-3H-l,2,4-triazol-3-on; en tautomer af en hvilken som helst af ovennævnte forbindelser; en stereoisomer af en hvilken som helst af ovennævnte forbindelser eller tautomerer; og et farmaceutisk acceptabelt salt af en hvilken som helst af ovennævnte forbindelser, tautomerer eller stereoisomerer.
- 11. Forbindelse ifølge krav 1, som er (S)—3—(1— ( (1 — acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 12. Forbindelse ifølge krav 1, som er (S)-3-(1-( (1- acryloylpyrrolidin-3-yl)amino)isoquinolin-3-yl)-1H-1,2,4-triazol-5 (4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 13. Forbindelse ifølge krav 1, som er (S)—3 — (8 — ( (1 — acryloylpyrrolidin-3-yl)oxy)-1,7-naphthyridin-6-yl)-1H-1,2,4-triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 14. Forbindelse ifølge krav 1, som er (S)—3 — (8 — ( (1 — acryloylpyrrolidin-3-yl)amino)-1,7-naphthyridin-6-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 15. Forbindelse ifølge krav 1, som er (S)-3-(1-( (1- acryloylpyrrolidin-3-yl)oxy)-8-fluorisoquinolin-3-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 16. Forbindelse ifølge krav 1, som er (S)-3-(1-( (1- acryloylpyrrolidin-3-yl) amino)-8-fluorisoquinolin-3-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 17. Forbindelse ifølge krav i, som er (S)—3 — (1— ( (1 — acryloylpyrrolidin-3-yl)oxy)-7-chlorisoquinolin-3-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 18. Forbindelse ifølge krav 1, som er (S)—3 — (1— ( (1 — acryloylpyrrolidin-3-yl) amino)-7-chlorisoquinolin-3-yl)-1H- 1.2.4- triazol-5 (4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 19. Forbindelse ifølge krav 1, som er (S)-3-(1-( (1- acryloylpyrrolidin-3-yl)oxy)-8-chlorisoquinolin-3-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 20. Forbindelse ifølge krav 1, som er (S)—3 — (1— ( (1 — acryloylpyrrolidin-3-yl) amino)-8-chlorisoquinolin-3-yl)-1H- 1.2.4- triazol-5(4H)-on, en tautomer deraf eller et farmaceutisk acceptabelt salt af forbindelsen eller tautomeren.
- 21. Farmaceutisk sammensætning, der omfatter: en forbindelse, en tautomer eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20; og et farmaceutisk acceptabelt excipiens.
- 22. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20 til anvendelse som et medikament.
- 23. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20 til anvendelse til behandling af en sygdom, forstyrrelse eller tilstand udvalgt blandt type I-overfølsomhedsreaktioner, autoimmunsygdomme, inflammationsforstyrrelser, cancer og ikke-maligne proliferative forstyrrelser.
- 24. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20 til anvendelse til behandling af en sygdom, forstyrrelse eller tilstand udvalgt blandt allergisk rhinitis, astma, atopisk dermatitis, rheumatoid arthritis, multipel sklerose, systemisk lupus erythematosus, lupus nephritis, psoriasis, immun trombocytopenisk purpura, inflammatorisk tarmsygdom, kronisk obstruktiv lungesygdom, Sjogrens syndrom, ankyloserende spondylitis, Behcets sygdom, graft-versus-host-sygdom, pemphigus vulgaris, idiopatisk plasmacytisk lymfadenopati, aterosklerose, myokardieinfarkt og trombose.
- 25. Forbindelse, tautomer eller farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20 til anvendelse til behandling af en sygdom, forstyrrelse eller tilstand udvalgt blandt B-cellelymfom, kronisk lymfocytisk leukæmi og multipelt myelom.
- 26. Kombination af en effektiv mængde af en forbindelse, en tautomer eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-20 og mindst ét yderligere farmakologisk aktivt middel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361776445P | 2013-03-11 | 2013-03-11 | |
PCT/US2014/022801 WO2014164558A1 (en) | 2013-03-11 | 2014-03-10 | Pyridinyl and fused pyridinyl triazolone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2970202T3 true DK2970202T3 (da) | 2017-05-08 |
Family
ID=50543655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14719130.8T DK2970202T3 (da) | 2013-03-11 | 2014-03-10 | Pyridinyl- og fusionerede pyridinyltriazolonderivater |
Country Status (42)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
CN104447530A (zh) * | 2014-12-11 | 2015-03-25 | 苏州欧凯医药技术有限公司 | 4-甲基-2,6-二羧基吡啶的制备方法 |
CN107257686B (zh) * | 2014-12-18 | 2021-01-29 | 普林斯匹亚生物制药公司 | 天疱疮的治疗 |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
US10836745B2 (en) * | 2015-12-24 | 2020-11-17 | Takeda Pharmaceutical Company Limited | Cocrystal, production method thereof, and medicament containing cocrystal |
HUE052893T2 (hu) * | 2016-01-13 | 2021-05-28 | Acerta Pharma Bv | Antifolát és BTK-gátló terápiás kombinációi |
WO2017173111A1 (en) | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
SG11201811255WA (en) | 2016-06-29 | 2019-01-30 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
WO2020021447A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3949963A4 (en) * | 2019-04-02 | 2023-01-04 | Yonsei University, University-Industry Foundation(UIF). | NEW COMPOUND AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES COMPRISING THIS AS AN ACTIVE PRINCIPLE |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AU2021325431B2 (en) | 2020-08-14 | 2024-01-18 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
US5733849A (en) * | 1996-03-15 | 1998-03-31 | Rohm And Haas Company | Halopyridyl triazolinone herbicides and herbicidal use thereof |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
IL139080A0 (en) | 1998-04-17 | 2001-11-25 | Parker Hughes Inst | Btx inhibitors and methods for their indentification and use |
CA2422367C (en) * | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
EP1981888A4 (en) | 2006-01-13 | 2010-10-13 | Pharmacyclics Inc | TYROSINE KINASE INHIBITORS AND USES THEREOF |
WO2007139967A2 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
WO2007147771A2 (en) | 2006-06-20 | 2007-12-27 | F. Hoffmann-La Roche Ag | Tetralin and indane derivatives and uses thereof |
AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
BRPI0907915A2 (pt) | 2008-02-05 | 2015-07-28 | Hoffmann La Rocha Ag F | Piridinonas e piridazinonas |
UA103327C2 (en) | 2008-06-24 | 2013-10-10 | Ф. Хоффманн-Ля Рош Аг | Substituted pyridin-2-ones and pyridazin-3-ones |
WO2010000633A1 (en) | 2008-07-02 | 2010-01-07 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
EP2307413B1 (en) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
AU2011253003B2 (en) | 2010-05-13 | 2014-05-01 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
MX367623B (es) | 2010-10-20 | 2019-08-29 | Gruenenthal Gmbh | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. |
WO2012064972A2 (en) | 2010-11-10 | 2012-05-18 | Stc.Unm | Aerosol reduction/expansion synthesis (a-res) for zero valent metal particles |
JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
-
2014
- 2014-03-05 JO JOP/2014/0070A patent/JO3377B1/ar active
- 2014-03-10 BR BR112015020264-0A patent/BR112015020264B1/pt active IP Right Grant
- 2014-03-10 AU AU2014249248A patent/AU2014249248B2/en active Active
- 2014-03-10 UA UAA201507597A patent/UA114944C2/uk unknown
- 2014-03-10 TW TW103108214A patent/TWI637950B/zh active
- 2014-03-10 GE GEAP201413953A patent/GEP201706778B/en unknown
- 2014-03-10 CN CN201480012902.5A patent/CN105121427B/zh active Active
- 2014-03-10 SG SG11201506112QA patent/SG11201506112QA/en unknown
- 2014-03-10 KR KR1020157028600A patent/KR102300612B1/ko active IP Right Grant
- 2014-03-10 LT LTEP14719130.8T patent/LT2970202T/lt unknown
- 2014-03-10 RS RS20170414A patent/RS55879B1/sr unknown
- 2014-03-10 JP JP2016501072A patent/JP6271700B2/ja active Active
- 2014-03-10 AP AP2015008646A patent/AP2015008646A0/xx unknown
- 2014-03-10 MA MA38391A patent/MA38391B1/fr unknown
- 2014-03-10 WO PCT/US2014/022801 patent/WO2014164558A1/en active Application Filing
- 2014-03-10 ME MEP-2017-98A patent/ME02693B/me unknown
- 2014-03-10 MY MYPI2015703082A patent/MY183927A/en unknown
- 2014-03-10 ES ES14719130.8T patent/ES2624439T3/es active Active
- 2014-03-10 UY UY0001035376A patent/UY35376A/es not_active Application Discontinuation
- 2014-03-10 ES ES17152008T patent/ES2714166T3/es active Active
- 2014-03-10 PT PT147191308T patent/PT2970202T/pt unknown
- 2014-03-10 HU HUE14719130A patent/HUE032720T2/en unknown
- 2014-03-10 DK DK14719130.8T patent/DK2970202T3/da active
- 2014-03-10 EP EP17152008.3A patent/EP3235814B1/en active Active
- 2014-03-10 SI SI201430203A patent/SI2970202T1/sl unknown
- 2014-03-10 EP EP14719130.8A patent/EP2970202B1/en active Active
- 2014-03-10 EA EA201591686A patent/EA028584B1/ru unknown
- 2014-03-10 PL PL14719130T patent/PL2970202T3/pl unknown
- 2014-03-10 US US14/203,366 patent/US9402841B2/en active Active
- 2014-03-10 MX MX2015011533A patent/MX364527B/es active IP Right Grant
- 2014-03-10 PE PE2015001905A patent/PE20151889A1/es active IP Right Grant
- 2014-03-10 CA CA2899948A patent/CA2899948C/en active Active
- 2014-03-10 AR ARP140100805A patent/AR095198A1/es active IP Right Grant
-
2015
- 2015-08-04 IL IL240353A patent/IL240353B/en active IP Right Grant
- 2015-08-06 DO DO2015000184A patent/DOP2015000184A/es unknown
- 2015-08-11 TN TN2015000342A patent/TN2015000342A1/en unknown
- 2015-08-19 ZA ZA2015/05996A patent/ZA201505996B/en unknown
- 2015-08-24 CL CL2015002370A patent/CL2015002370A1/es unknown
- 2015-09-10 CR CR20150470A patent/CR20150470A/es unknown
- 2015-09-10 PH PH12015502046A patent/PH12015502046A1/en unknown
- 2015-10-08 EC ECIEPI201542779A patent/ECSP15042779A/es unknown
-
2016
- 2016-06-29 US US15/197,051 patent/US9801872B2/en active Active
- 2016-07-12 HK HK16108174.3A patent/HK1220183A1/zh unknown
-
2017
- 2017-04-20 HR HRP20170622TT patent/HRP20170622T1/hr unknown
- 2017-04-25 CY CY20171100458T patent/CY1119356T1/el unknown
- 2017-09-27 US US15/717,624 patent/US10307414B2/en active Active
- 2017-12-27 JP JP2017252294A patent/JP6462842B2/ja active Active
-
2018
- 2018-04-06 HK HK18104553.1A patent/HK1245256B/zh unknown
-
2019
- 2019-04-03 US US16/374,430 patent/US20190224190A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2970202T3 (da) | Pyridinyl- og fusionerede pyridinyltriazolonderivater | |
JP2022110135A (ja) | Syk阻害剤としての縮合複素芳香族ピロリジノン | |
EP2678342B1 (en) | N-substituted oxazinopteridines and oxazinopteridinones | |
US9365566B2 (en) | Cinnoline derivatives | |
US9663514B2 (en) | Substituted 6-aza-isoindolin-1-one derivatives | |
AU2013288895A1 (en) | Azaindole derivatives which act as PI3K inhibitors | |
WO2015106012A1 (en) | Azaindole derivatives | |
WO2020198053A1 (en) | 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases | |
WO2022066917A1 (en) | 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors | |
NZ710852B2 (en) | Pyridinyl and fused pyridinyl triazolone derivatives |